Pfizer (PFE)

by | Jul 28, 2020 | Daily Trade Alert

On July 13, we highlighted Pfizer (PFE) as an opportunity at $34.63 after the US FDA fast-tracked its vaccine candidates.

Today, the stock is up to $38.70, where we are reiterating a buy recommendation.

For one, the company just beat earnings expectations and raised its full-year guidance.

The company posted a profit of 78 cents, which was well above estimates for 66 cents. Revenue of $11.8 billion beat estimates for $11.55 billion. Going forward, Pfizer expects to post revenue of $48.6 billion to $50.6 billion, a $100 million increase from prior forecasts. It also expects to posted adjusted EPS of $2.85 to $2.95 a share.

Better, Pfizer and BioNTech just began late-stage human trials for a COVID-19 vaccine.

As we hear more about the trials, we believe the PFE stock has the potential to move another 50% higher – especially given the demand for a useful vaccine.

Tech Stocks to Drop 92%?? (stunning prediction)

The firm that called the EXACT PEAK of the Dot-Com boom has just issued another major prediction.

If you’ve got money invested in the market – and especially in popular tech stocks – this is critical information for the days ahead…

Watch the Video

Related Content